Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.
BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.
Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.
Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.
For more information and the latest updates, visit the SEC's website.
BioSig Technologies (Nasdaq: BSGM) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3 PM ET. CEO Ken Londoner will share insights about the company’s PURE EP™ System, which enhances signal fidelity in electrophysiology. This system has been utilized by over 40 physicians in more than 600 patient cases across eight clinical sites. Interested parties can schedule one-on-one meetings and view the live webcast via the provided links.
BioSig Technologies, Inc. (NASDAQ: BSGM) has announced that the U.S. Patent Office allowed a utility patent for its PURE EP™ technology, focusing on noise-filtering methods for cardiac signals. This innovation is crucial for accurately diagnosing and treating cardiac arrhythmias, particularly atrial fibrillation, which affects over 6 million Americans. The company now holds 34 patents globally for its PURE EP™ technology, enhancing its competitive position in the medical technology market. This new patent complements its patent portfolio and will assist medical teams in improving patient outcomes.
BioSig Technologies (NASDAQ: BSGM) announced significant advances in its operations, including the first commercial sale of the PURE EP™ System to St. David’s HealthCare and over 643 patient cases conducted. The company is expanding its clinical reach with additional sites due to begin evaluations soon. Furthermore, BioSig is developing novel nerve sensing technology and artificial intelligence solutions in collaboration with Mayo Clinic. With a robust cash position of $28.3 million, BioSig is poised for growth and innovation in 2021.
BioSig Technologies, Inc. (Nasdaq: BSGM) will present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Kenneth L. Londoner, Chairman and CEO, is scheduled to speak on March 25th at 12:20 PM ET. He will discuss recent milestones related to the PURE EP™ System, an advanced platform aimed at improving cardiac ablations. Over 40 physicians have utilized the system in more than 600 patient cases across eight clinical sites. One-on-one meetings with management can be scheduled through links provided in the release.
BioSig Technologies (Nasdaq: BSGM) has been invited to the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021. Kenneth L. Londoner, Chairman and CEO, will participate in a virtual fireside chat at 8:00 AM ET and is available for investor meetings. BioSig's PURE EP™ System enhances signal fidelity for cardiac ablation procedures, with over 38 physicians completing more than 580 cases across 7 clinical sites. A replay of the chat will be accessible for 90 days post-event.
BioSig Technologies, a medical technology firm, will present at the 33rd Annual Virtual ROTH Conference from March 15-17, 2021. CEO Kenneth L. Londoner will discuss the company's progress and provide an overview of BioSig's innovative PURE EP™ System, which improves ECG signal fidelity and has been used in over 580 patient cases by more than 38 physicians. The presentation will be accessible online starting March 10, 2021, and available for 90 days. The conference, featuring numerous companies, attracts institutional investors and analysts.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the allowance of a utility patent for its subsidiary NeuroClear Technologies, licensed from the Mayo Foundation. This patent focuses on methods to enhance hypertension treatment through electroporation. It complements BioSig's expanding portfolio of nine allowed patents and 16 pending patent applications related to their PURE EP™ System. The company aims to develop its N-SENSE™ platform to address neurological conditions, utilizing innovative sensing designs and algorithms.
BioSig Technologies has appointed Brenda Castrodad as the new head of its Human Resources department to support the demand for its PURE EP System. With experience in life sciences at both start-ups and Fortune 500 companies, she previously transformed HR at TissueTech and expanded HeartWare's workforce significantly. Castrodad's expertise is expected to enhance talent acquisition and employee engagement amidst BioSig's growth trajectory. CEO Kenneth L. Londoner expressed confidence in her ability to drive innovation and success within the company.
BioSig Technologies, a medical technology firm, has entered into three new evaluation agreements for its PURE EP™ System, reducing assessment cycles to 90 days. This shift follows successful evaluations in 2020 and aims to facilitate rapid commercialization. The new clinical sites, including prestigious hospitals like New York-Presbyterian and Michigan Medicine, will enhance the system's deployment. Over 500 patient cases have already been recorded using the PURE EP™ System. The company anticipates increased activity in 2021, driven by declining COVID-19 cases.
BioSig Technologies, Inc. (Nasdaq: BSGM) has announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. During the event, Kenneth L. Londoner, Chairman and CEO, will present a corporate overview, including updates on the rollout of their innovative PURE EP™ System. Over 470 patient procedures have been successfully conducted using this system across seven clinical sites in the U.S. The presentation is scheduled for 11:30 AM Eastern time.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
What does BioSig Technologies, Inc. do?
What is the PURE EP™ Platform?
Who are BioSig's collaborators?
What recent achievements has BioSig made?
How is BioSig addressing its financial and operational challenges?
What are BioSig's future plans?
How does the NFT algorithm benefit clinical procedures?
Is BioSig publicly traded?
What steps has BioSig taken to comply with Nasdaq requirements?
Where can I find more information about BioSig?
